By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Following a patent licensing deal with Cell Signaling Technology, Pfizer will grant a sub-license to Abbott to develop a companion diagnostic test for selecting patients to be treated with Pfizer's crizotinib, an investigational anaplastic lymphoma kinase inhibitor.

Abbott will develop a fluorescence in situ hybridization-based test, under the terms of the sub-license.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.